Research focus

Intensive care medicine

In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).

Continuing this practice, Biotest is developing the IgM and IgA-enriched polyvalent antibody preparation  trimodulin for the treatment of severe community acquired pneumonia. The similarity of symptoms in severe COVID-19 to symptoms of sCAP patients suggests a considerable potential for trimodulin also in the treatment of SARS-CoV-2 induced pneumonia.

Moreover, we are developing an innovative fibrinogen concentrate, used amongst others to treat life-threatening bleedings. 

Intensive care medicine pipeline

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

Trimodulin
BT588

Severe COVID-19

Trimodulin

BT588
Severe COVID-19

 

Trimodulin
BT588

Severe community acquired pneumonia

Trimodulin

BT588
Severe community acquired pneumonia

 

Fibrinogen
BT524

Congenital fibrinogen deficiency

Fibrinogen

BT524
Congenital fibrinogen deficiency

 

Fibrinogen
BT524

Acquired fibrinogen deficiency

Fibrinogen

BT524
Acquired fibrinogen deficiency